Q-omics provides the consensus-scored MIR30C2 profile across patient tissues and cancer cell-line models. MIR30C2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR30C2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, MIR30C2 RNA expression shows 16,851 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight ACC, KIRC, and KIRP as cancer lineages where MIR30C2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR30C2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR30C2 survival associations across molecular data types. MIR30C2 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR30C2 RNA expression–survival associations across cancer types. High MIR30C2 expression shows unfavorable associations in PAAD and BLCA, but favorable associations in ACC, BRCA, CESC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .008). Together, the overview and detailed table identify ACC as the clearest survival context for MIR30C2 RNA expression.
This table summarizes MIR30C2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR30C2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR30C2 shows lower tumor expression in KIRC, BLCA, THCA, LUSC, LUAD and BRCA. The KIRC box plot shows higher MIR30C2 RNA expression in normal versus tumor tissue (log2 FC = −0.997, t-test p < 0.001).
This table shows molecular features associated with MIR30C2 in patient tissues and cancer cell lines. In patient samples, MIR30C2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
